Alnylam Pharmaceuticals (ALNY) Liabilities and Shareholders Equity (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $5.6 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 21.74% year-over-year to $5.6 billion; the trailing twelve-month figure through Jun 2026 stood at $20.5 billion (up 19.05% YoY), and the FY2025 full-year result was $5.0 billion, up 17.13% from the prior year.
• Liabilities and Shareholders Equity advanced to $5.6 billion in Q2 2026 per ALNY's latest filing, from $5.1 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $5.6 billion in Q2 2026 and bottomed at $3.3 billion in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $4.1 billion across 5 years, with a median of $3.9 billion in 2023.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity declined 5.1% in 2022, then grew 21.74% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $3.5 billion in 2022, then increased by 7.99% to $3.8 billion in 2023, then rose by 10.71% to $4.2 billion in 2024, then climbed by 17.13% to $5.0 billion in 2025, then climbed by 11.93% to $5.6 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $5.6 billion, $5.1 billion, and $5.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.